Stryker’s Trauma & Extremities division has launched its Citrelock™ Tendon Fixation Device System. The new system provides surgeons a differentiated design via a tendon thread featuring a resorbable technology, known as Citregen™, that has unique chemical and mechanical properties for orthopaedic surgical applications. Stryker will debut Citrelock at the American Orthopaedic Foot & Ankle Society (AOFAS) Annual Meeting, Sept. 22-25, 2021, in Charlotte, N.C. The Citrelock Tendon Fixation Device System offers surgeons: A controlled and homogeneous resorption process that prevents bulk degradation and chronic inflammation. Compressive strength that is comparable to cortical bone with a modulus comparable to cancellous bone. Citregen contains citrate, calcium, and phosphate molecules that are inherent to the bone anatomy. Material polymer structure that mimics the extracellular matrix protein network. Citregen maintains structural integrity during the healing phase, while the implant is replaced by host tissue over time.